China’s synthetic biology startup ecosystem experienced rapid development from nascent to initial maturity over the past five years. Around 2020, the first wave of academic spinoffs attracted capital attention; 2021–2022 saw a funding peak (multiple companies completing hundreds of millions in Series A/B); post-2023, funding rationalized as leading companies push toward IPO or strategic partnerships.
## Core Startup Map
**Materials track**: Bluepha (Beijing) — polyhydroxyalkanoates (PHA) biodegradable materials, fully bio-based and fully biodegradable; among the closest-to-market bio-based plastics; ten-thousand-ton fermentation capacity built. Wecrobes (Shanghai) — also PHA-focused; backed by Sequoia, IDG Capital.
**Pharmaceutical track**: EdiGene — gene editing + cell therapy, CAR-T/CAR-NK platforms. EdiGene Biopharma — hematopoietic stem cell gene editing for β-thalassemia.
**Chemical/agricultural track**: Morimatsu — industrial enzymes and bio-based chemicals for bulk chemical biological substitution. Cathay Industrial (listed) — bio-based PA56; the listed benchmark company in synthetic biology, providing a complete “lab to A-share” pathway reference.
**Biofoundry track**: DP Technology — AI + biomolecular dynamics simulation platform for protein and materials design. MegaRobo — lab automation robots accelerating synthetic biology DBTL cycles.
## Funding and Exit Landscape
Major investors: Shenzhen Capital Group, Sequoia China, IDG Capital, GL Ventures (Hillhouse), Frees Fund. Government industrial funds (Shanghai Biomed Industrial Park, Shenzhen Pingshan) provide subsidies and facilities for early-stage companies. Exit paths: A-share STAR Market (Cathay Industrial model); Hong Kong Stock Exchange Chapter 18A (pre-profit biotech); or acquisition by large pharma/chemical companies.
See [Synthetic Biology Overview](https://sunqi.org/synthetic-biology-overview-en/) and [Biomanufacturing and Fermentation](https://sunqi.org/biomanufacturing-fermentation-en/).
